Evidence map›Paper›PMID 36307538›Full record

ArticleScientific reports2022

Design and characterization of an urea-bridged PMO supporting Cu(II) nanoparticles as highly efficient heterogeneous catalyst for synthesis of tetrazole derivatives.

Ehsan Valiey, Mohammad G Dekamin

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Mesoporous SBA-16/SOScientific reports · 2025
    Article
  3. FeScientific reports · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ehsan ValieyPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran.
Mohammad G DekaminPharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran. mdekamin@iust.ac.ir.

Funding

The Research Council of Iran University of Science and Technology (IUST), Tehran, Iran 160/20969
6 · The paper itself

Abstract

In this work, a new periodic mesoporous organosilica with urea-bridges produced by the reaction of (3-aminopropyl)triethoxysilane and toluene-2,4-diisocyanate (APS-TDU-PMO) is introduced. The obtained APS-TDU-PMO was found to be an appropriate support for loading of Cu(II) nanoparticles to afford supramolecular Cu@APS-TDU-PMO nanocomposite. Uniformity and mesoporosity of both synthesized nanomaterials including APS-TDU-PMO and Cu@APS-TDU-PMO were proved by different spectroscopic, microscopic or analytical techniques including FTIR, EDX, XRD, FESEM, TEM, BET, TGA and DTA. Furthermore, the prepared Cu@APS-TDU-PMO nanomaterial was also used, as a heterogeneous and recyclable catalyst, for the synthesis of tetrazole derivatives through cascade condensation, concerted cycloaddition and tautomerization reactions. Indeed, the main advantages of this Cu@APS-TDU-PMO is its simple preparation and high catalytic activity as well as proper surface area which enable it to work under solvent-free conditions. Also, the introduced Cu@APS-TDU-PMO heterogeneous catalyst showed good stability and reusability for six consecutive runs to address more green chemistry principles.

Indexed as

NanocompositesNanoparticlesCatalysisCopperMetal NanoparticlesTetrazolesUreaCopperTetrazolesUrea

Identifiers

PMID36307538
PMCPMC9616949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.